New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
10:55 EDTABT, ABT, AZN, AZN, CELG, CELG, INCY, INCY, LLY, LLY, PFE, PFE, RIGL, RIGLLeerink's major pharmaceuticals and biotech analysts hold a conference call
Major Pharmaceuticals Analyst Fernandez and Biotech Analysts Kozul and Liang provide insights from the American College of Rheumatology's Annual Meeting on an Analyst/Industry conference call. Relevant covered companies ABT, AZN, CELG, INCY, LLY, PFE and RIGL may be included on the Analyst/Industry conference call to be held on November 14 at 11 am.
News For ABT;AZN;CELG;INCY;LLY;PFE;RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 21, 2014
08:32 EDTLLYFDA accepted NDA for empagliflozin plus
Subscribe for More Information
07:54 EDTINCYLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
07:44 EDTABTAbbott volatility elevated into Q3 and outlook
Subscribe for More Information
07:15 EDTPFE, LLY, AZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTPFEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas – influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
07:47 EDTPFE, AZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
13:18 EDTCELGLeerink's biotech analyst holds an analyst/industry conference call
Subscribe for More Information
10:51 EDTLLYOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
08:01 EDTINCYIncyte names Gryska CFO to succeed Hastings
Incyte announced the appointment of David Gryska as Executive Vice President and CFO, effective October 31. Gryska will succeed David Hastings, who has served as Incyte’s Executive Vice President and CFO since October 2003. Hastings, who is leaving the company to pursue other opportunities, will remain with Incyte through the end of November and will work closely with Gryska to ensure a seamless transition.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use